### Attorney Docket No. 55461-C2 (45487)

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Bjarne Due LARSEN, et al.

U.S.S.N.:

Unassigned

EXAMINER: Unassigned

FILED: February 4, 2004

**GROUP: Unassigned** 

FOR: NOVEL ANTIARRYTHMIC PEPTIDES

#### CERTIFICATE OF EXPRESS MAIL

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as "Express Mail Post Office to Addressee" Mailing Label No. EV438994174US in an envelope addressed to the: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on February 4, 2004.

Patricia A. Barnes

COMMISSIONER FOR PATENTS P. O. BOX 1450 ALEXANDRIA, VA 22313-1450

Date: February 4, 2004

Sir:

## INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

#### I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION

The patents, publications or other information submitted for consideration by the Office are listed on PTO-1449, attached hereto.

II.	COPIES					
	a	Submitted herewith is a legible copy of (i) each U.S and foreign patent; (ii) each publication or that portion which caused it to be listed; and (iii) all other information or that portion which caused it to be listed.				
	b <u>.</u>	This application relies, under 35 U.S.C. § 120, on the earlier filing date of prior application Serial No, filed on The following references were submitted to, and/or cited by, the Office in the prior application (s) and, therefore, are not required to be provided in this application.				
III.	CONCISE EXPLANATION OF THE RELEVANCE (check at least one box)					
	a	Except as may be indicated below in (b), all of the patents, publications or other information are in the English language or were cited in an English language Search Report, a copy of which is attached hereto (concise explanation not required).				
	b	A concise explanation of the relevance of all patents, publications or other information listed that is not in the English language is as follows:				
	c	The following additional information is provided for the Examiner's consideration.				
		<u>FEES</u>				
IV.	THIS IDS IS BEING FILED UNDER 37 C.F.R. § 1.97(b) (check one box)					
	a	within three months of the filing date of a national application (37 C.F.R. § 1.97(b) (1]. No fee or certification is required.				
	b	within three months of the date of entry of the national stage as set forth in §1.491 in an international application (37 C.F.R. § 1.97(b) (2). No fee or certification is required.				

11

.

	c	Before the mailing date of a first Action on the merits (37 C.F.R. § 1.97(b) (3)). No fee or certification is required. In the event that a first Office Action on the merits has been issued, please consider this IDS under 37 C.F.R. § 1.97(c) and see the certification under 37 C.F.R. § 1.97(e) below, or, if no certification has been made, charge our deposit account a fee in the amount of \$180.00 as required by 37 C.F.R. § 1.17(p).					
V.	THIS IDS IS BEING FILED UNDER 37 C.F.R. § 1.97(c): (check one box)						
	before the mailing date of a Final Office Action under 37 C.F.R. § 1.113 (See 37 C.F.R. § 1.97(c) (1)) or before the mailing date of a Notice of Allowance under 37 C.F.R. § 1.311 (See 37 C.F.R. § 1.97(c) (2)).						
	a	No certification; therefore, a fee in the amount of \$180.00 is required by 37 C.F.R. §1.17(p).					
	b	or See the certification below. No fee is required.					
VI.	STATEMENT UNDER 37 C.F.R. § 1.97(e) (check only one box)						
The u	ndersigned he	ereby states that					
	a	each item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS; or					
	b	no item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application or, to the best of my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this statement.					

.

Some of the items of information were cited in a communication from a foreign Patent Office. As to this information, the undersigned certifies that each item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS. As to the remaining information, the undersigned hereby certifies that no item of this remaining information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application or, to the best of my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this statement. Please charge Deposit Account No. 04-1105 in the amount of \$180.00 for the above-indicated fee. A triplicate copy of this paper is attached. X No fee is required.

If the Examiner has any questions concerning this IDS, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule, with a petition if necessary, and charge the appropriate fee to Deposit Account No. **04-1105**.

Respectfully submitted,

Date: 4 Hb 2004

Robert L. Buchanan Reg. No. 40,927 Attorney for Applicant(s)

EDWARDS & ANGELL, LLP P. O. Box 55874 Boston, MA 02205 Tel: (617) 439-4444

Fax: (617) 439-4170 / 7748

Customer No.: 21874

#432780

FORM PTO-1449			DOCKET NO:		SERI	AL NO.:	
INFORMATION DISCLOSURE STATEMENT			55461-C2 (45487)		Unassigned		
			l		GROUP N		
		February 2, 2004		Unassi	gned		
		UNITED S	STATES PATENT DOCU	MEN	TS		
	DOCUMENT NUMBER	DATE NAME		CLASS		SUBCLASS	FILING DATE IF APPROPRI ATE
AA	4,775,743	10/04/88	Mimura et al.				09/10/86
	·						
		-					
		· · · · · · · · · · · · · · · · · · ·					
				_			
		a.c.ru					
	<b>.</b>	FORE	IGN PATENT DOCUMEN	NTS			
	DOCUMENT NUMBER	DATE	COUNTRY		CLASS	SUBCLASS	TRANSLAT ION YES/NO
ВА	WO 96/21674	18/07/96	PCT				
ВВ	DE 19707854 A 1	03/09/98	Germany				No
от	HER DOCUMEN	TS (INCLUDIN	IG AUTHOR, TITLE, DA	TE, P	ERTINEN	IT PAGES, ETC.	)
CA							
EXAMINER:					DATE:		
	BA BB OTT	DOCUMENT NUMBER  DOCUMENT NUMBER  DOCUMENT NUMBER  BA WO 96/21674  BB DE 19707854 A 1  OTHER DOCUMENT CA	UNITED S	S5461-C2 (45487)   APPLICANT(S): Bjame   FILING DATE: February 2, 2004	S5461-C2 (45487)   APPLICANT(S): Bjame Due     FILING DATE:     February 2, 2004	S5461-C2 (45487)   Unast	TION DISCLOSURE STATEMENT

E0714 PTO 1440				DOCKETNO. CEDIAL NO.				
FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT				DOCKET NO:		SERIAL NO.: Unassigned		
				55461-C2 (45487)	Unas			
				APPLICANT(S): Bjarne Due Larsen, et al.				
				FILING DATE: GROUP NO.:				
				February 2, 2004	Unassigned			
				<u>. H </u>	-4			
			UNITE	D STATES PATENT DOCUM	ENTS	•		
EXAM.		DOCUMENT					FILING DATE	
INITIALS		NUMBER	DATE	NAME	CLASS	SUBCLASS	IF	
	<u> </u>	ļ		<del> </del>			APPROPRIATE	
		<u> </u>			<u> </u>			
	Ĺ	<u></u>		<u> </u>		<u> </u>	<u> </u>	
			FOI		TO.			
	ı —	D. C. C. D.	T	REIGN PATENT DOCUMENT	15	T	T	
•		DOCUMENT	DATE	COMMENT	CT ACC	CITE CI ACC	TRANSLATION	
	<u> </u>	NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	YES/NO	
	BA	0 214 659 A	18. 03.87	Europe		ļ	Y	
				<u></u>		<u> </u>		
· · · · · · · · · · · · · · · · · · ·		THER DOCUMI	ENTS (INCLUE	DING AUTHOR, TITLE, DAT	E, PERTINE	NT PAGES, ET	·C.)	
	CA Y. Kohama, et al. "Effect of N-3-(4-Hydroxyphenyl) propionyl Pro-Pro-Gly-Ala-Gly on Calcium-Induced Arrhythmias", CHEMICAL & PHARMACEUTICAL BULLETIN, Vol. 36, No. 11, 1988, pp. 4597-4599.							
		S. Dhein, et al. "Therapeutic Potential of Antiarrhythmic Peptides", DRUGS, Vol. 49, No. 6, 1995, pp. 851-855.						
	}	B. Kundu "Synthesis, conformational features and biological activity of Pro-3 antiarrhythmic peptide", COLLECTION OF CZECHOSLOVAK CHEMICAL COMMUNICATIONS, Vol. 54, No. 3, 1989, pp. 760-771.						
	CD	B. Weinstein "Chemistry and Biochemistry of Amino Acids, Peptides and Proteins" 1982, MARCEL DEKKER INC., NEW YORK AND BASEL, page 357.						
EXAMINER:				•	DATE:			
					·		•	

Sheet 2 of 2